In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.
In July, the six viral marker assay conversion at CTS Dallas, Phoenix and Tampa laboratories was ach...
Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...
CTS Research Consortium was established to further CTS’s leadership in infectious disease research....
Continue to meet or exceed healthcare partners’ expectations by providing on-time test results appr...
By the end of 2017, CTS has secured three source plasma partners and continues to seek additional pa...
CTS Tampa lab implemented the Ortho Clinical Diagnostics VITROS® testing platform to perform COVID-1...